TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.

J Immunother Cancer · 2019 · PMC6880482 · PMID 31771649

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

These data demonstrate that highly significant improvements in survival and cure rate for bilateral melanoma can be achieved by using higher potency TLR9 and CTLA-4 blocking / depleting antibodies.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.